Drugs / Eftilagimod Alfa
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07102940 | Sep 2026 → Aug 2028 expected | Her2-receptor negative breast cancer | George Washington University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06128863 | Jul 2023 → Apr 2025 overdue | soft tissue sarcoma | Maria Sklodowska-Curie National Research Institute of Oncology | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06726265 | Mar 2025 → Jun 2027 expected | non-small cell lung carcinoma | Immutep S.A.S. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eftilagimod Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07102940 ↗ |
| Known as | Efti | “Eftilagimod Alfa (Efti) will be administered subcutaneously at a dose of 30 mg beginning of week 1 of the trial for a total of 3 doses (week 1, 2 and 3).” NCT07102940 ↗ |
| Action | Activate | “Eftilagimod alfa (efti) activates antigen-presenting cells, triggering T cell activation and a sustained immune response.” PMID 41383151 ↗ Dec 2025 |
| Modality | Protein / enzyme biologic | “a soluble LAG-3 protein, eftilagimod alfa (Efti)” NCT06128863 ↗ |
| Route | Subcutaneous | “Eftilagimod alfa 20 mg s.c. every 2 weeks (5 doses)” NCT06128863 ↗ |